Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA3000
- Development stage
- Discontinued
- Lead developer
- Parent
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
MVA3000 is an attenuated (non-replicating) Modified Vaccinia Ankara (MVA) smallpox vaccine developed for use in individuals for whom the traditional live vaccinia virus-based smallpox vaccines are contraindicated, such as those with immune system disorders or skin conditions like eczema. Unlike conventional smallpox vaccines, which can cause serious side effects in certain populations due to their ability to replicate in human cells, MVA3000 uses a highly attenuated strain of vaccinia that cannot replicate in human cells. This makes it safer for immunocompromised individuals and those with atopic dermatitis. The primary mechanism of action is immunostimulation—eliciting an immune response against the variola virus (smallpox). It was co-developed by Acambis and Baxter Healthcare[1][5][6][8].
- Other names
- Modified Vaccinia Ankara smallpox vaccine
02
Targets
Vaccinia virus antigen
Beyond the preview
Go deeper on MVA3000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA3000.